|
President and CEO of Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals Inc. and Isis Pharmaceuticals Inc., that focuses on microRNA technology, which controls protein production within cells and could be used to turn off certain genes, in effect treating a condition at the genetic level. Prior to joining Regulus, Dr. Xanthopoulos served as a Managing Director at Enterprise Partners Venture Capital in the Life Sciences practice. He is also a co-founder, former President and CEO of Anadys Pharmaceuticals and still serves on its Board of Directors since May 2000. From 1997 to 2000 he held a variety of positions at Aurora Biosciences Corporation, including Vice President, Genomics & Molecular Biology. Dr. Xanthopoulos was a Section Head of the National Human Genome Research Institute at The National Institutes of Health. and was a Postdoctoral Research Fellow at the Rockefeller University from 1987 to 1990 and an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Sweden from 1991 to 1995. Dr. Xanthopoulos is also an executive board member of BIOCOM, Southern California's life science industry association. An Onassis Scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. | 